Vienna (ots/PRNewswire) - People treated with Saxenda® (liraglutide 3 mg) for weight management lost an average of 8.1 kg after six months in a real-world clinical setting, in combination with diet and exercise. The data were presented this week at both the 25th European Congress on Obesity (ECO 2018) in Vienna, Austria and the 23rd Annual International Meeting of the ...
Munich (ots/PRNewswire) - - Sub-analysis presented from ENGAGE AF-TIMI 48, the longest single comparative global trial of a non-vitamin K oral anticoagulant (NOAC) in patients with non-valvular atrial fibrillation (NVAF) to date - Results showed a reduction in both spontaneous and traumatic intracranial haemorrhage ...
Novato, California, Tokyo and London (ots/PRNewswire) - Substantial Healing of Rickets Observed in 72% of Patients Treated with Crysvita Compared to 6% of Patients Receiving Conventional Therapy at 40 Weeks Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media ASCO Abstract # ERBITUX® (cetuximab): 3521, 3534, e15711; avelumab: 9507, 9537, 9090, 9008, 8563, 3057, 4544, e21531, e13603, e18932, e21623, e21620, e21544; tepotinib (c-Met kinase inhibitor): 9082, 9016; M6620 (ATR inhibitor): 2549, e21048; M3814 (DNA-PK): 2518 M7824 (TGF-ß ...
EQS Group-News: Polyphor AG / Key word(s): Scientific publication/Study results Polyphor announces publication of positive proof of concept data for innovative immuno-oncology candidate balixafortide in The Lancet Oncology 30.04.2018 / 07:00 680657 30.04.2018 ...
Brussels (ots/PRNewswire) - Strictly not for UK/Irish media - CIMZIA® (certolizumab pegol) Phase 3 psoriasis data demonstrated significant and clinically meaningful improvements in biologic-naïve and previously treated patients, with clinical benefit maintained up to one year[1] - This milestone represents UCB's ...
EQS Group-Ad-hoc: Airopack Technology Group AG / Key word(s): AGM/EGM Airopack Technology Group AG: Changes to the Board of Directors and Publication of Invitation to Annual General Meeting of Shareholders of 18 April 2018 23-March-2018 / 06:51 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The ...
Chicago (ots/PRNewswire) - Oral session #12 Adults with obesity treated with semaglutide 0.4 mg administered once-daily via subcutaneous injections lost up to 13.8% of their body weight after 52 weeks in a phase 2 trial, significantly more than those treated with placebo who lost 2.3% of their body weight.[1] An ...
Takeda Pharmaceutical Company Limited
Osaka, Japan (ots/PRNewswire) - New clinical study also provides data for Entyvio® in inducing complete mucosal healing and endoscopic remission, particularly in bio-naïve patients Takeda Pharmaceutical Company Limited (TSE: 4502) ("Takeda") today announced new real-world data evaluating the comparative ...
Bagsværd, Denmark (ots/PRNewswire) - Results from the SUSTAIN 7 trial, which investigated the efficacy and safety of 0.5 mg semaglutide compared with 0.75 mg dulaglutide and 1.0 mg semaglutide compared with 1.5 mg dulaglutide, when added to metformin, have been published in The Lancet Diabetes & Endocrinology.[1] ...
Nuremberg, Germany (ots/PRNewswire) - - Sydney knocks New York off 3rd place, while Melbourne jumps from 9th to 7th - Tokyo records greatest score gain of all 50 cities The latest Anholt-GfK City Brands IndexSM (CBISM) reveals that Paris retains its position at the top. For the fourth time since the survey began, the global public regards Paris as the highest rated out of 50 cities. Australian cities also show ...
Brussels (ots/PRNewswire) - - European Medicines Agency (EMA) has approved label change for UCB's CIMZIA® (certolizumab pegol), making it the first anti-TNF for potential use in women with chronic rheumatic disease, during both pregnancy and breastfeeding - Data submitted to regulatory authorities included ...
Munich (ots/PRNewswire) - For EU media only - not for US journalists - Hokusai-VTE CANCER study is a phase 3b, prospective, randomised, open-label, blind end-point (PROBE) study evaluating edoxaban versus low molecular weight heparin (LMWH) dalteparin in venous thromboembolism (VTE) associated with primarily active ...
Bagsværd, Denmark (ots/PRNewswire) - - Results published in Diabetes, Obesity and Metabolism Newly published data from real-world European clinical practice has shown that Xultophy® (insulin degludec/liraglutide) significantly reduced blood sugar levels in people with type 2 diabetes after six months.[1] The study ...
Abu Dhabi, Uae (ots/PRNewswire) - In people with type 2 diabetes who fast during Ramadan, Ryzodeg® (insulin degludec/insulin aspart) reduced the overall rate of low blood sugar (hypoglycaemia) including severe episodes by 62% and the rate of nocturnal hypoglycaemia by 74% versus biphasic insulin aspart 30 (BIAsp 30 ...
Abu Dhabi, Uae (ots/PRNewswire) - People with either type 1 or type 2 diabetes treated with Tresiba® had fewer episodes of low blood sugar (hypoglycaemia) compared with people on insulin glargine U100 regardless of whether they had achieved blood sugar targets.[1] These new post-hoc analyses from the SWITCH 1 and 2 trials were presented at the International Diabetes Federation (IDF) Annual Congress in Abu Dhabi ...
Bagsværd, Denmark (ots/PRNewswire) - - Switching to Tresiba® reduced the rate of hypoglycaemia by 67% in people with controlled blood sugar levels - In people with diabetes whose blood sugar was too high, switching to Tresiba® significantly improved blood sugar levels Switching to Tresiba® from another basal ...
Québec, Canada (ots) - GenePOC Inc. (GenePOC), a member of the Debiopharm Group(TM), is proud to announce the launch of its 2nd FDA cleared assay in less than 6 months, GenePOC(TM) CDiff, for use on the revogene(TM) instrument. The GenePOC CDiff test targets the toxin B gene of toxigenic C. difficile strains in ...
Aberdeen, Scotland (ots/PRNewswire) - Bibby Offshore Holdings Limited ("Bibby Offshore" or the "Group"), is delighted to announce that it has reached a comprehensive agreement on the recapitalisation of its balance sheet with noteholders who hold 80% of the £175 million 7.5% senior secured notes due 15 June 2021 ...
DGAP-News: Highlight Communications AG / Key word(s): 9-month figures 3Q2017: Highlight Group remains on track after nine months 22.11.2017 / 18:00 The issuer is solely responsible for the content of this announcement. 631933 22.11.2017 ...
World Innovation Summit for Education (WISE)
Doha, Qatar (ots/PRNewswire) - The prestigious WISE Prize for Education has been presented to Mr Patrick Awuah, founder and president of Ashesi University College, a private, not-for-profit institution that has become one of Ghana's premier universities in little over a decade. Her Highness Sheikha Moza bint Nasser, ...
Beerse, Belgium (ots/PRNewswire) - FOR MEDICAL AND TRADE MEDIA ONLY - 60% of patients receiving ustekinumab showed significant reductions in lupus disease activity vs. 31% of patients receiving placebo - Ustekinumab showed significant improvements in various disease measures compared with placebo, including ...
Beerse, Belgium (ots/PRNewswire) - FOR MEDICAL AND TRADE MEDIA ONLY Longer-term results demonstrate continued efficacy of anti-interleukin 23 monoclonal antibody guselkumab in improving joint and skin symptoms associated with active psoriatic arthritis Janssen Research & Development, LLC (Janssen) announced today ...
Beerse, Belgium (ots/PRNewswire) - FOR MEDICAL AND TRADE MEDIA ONLY Longer-term results demonstrate continued efficacy of anti-interleukin 23 monoclonal antibody guselkumab in improving joint and skin symptoms associated with active psoriatic arthritis Janssen Research & Development, LLC (Janssen) announced today ...
Beerse, Belgium (ots/PRNewswire) - FOR MEDICAL AND TRADE MEDIA ONLY - 60% of patients receiving ustekinumab showed significant reductions in lupus disease activity vs. 31% of patients receiving placebo - Ustekinumab showed significant improvements in various disease measures compared with placebo, including ...
San Diego and London (ots/PRNewswire) - Findings from a new multi-country GSK survey, released today to coincide with the 2017 American College of Rheumatology/Association for Rheumatology Health Professionals Annual Meeting (ACR/AHRP), reveal that patients with systemic lupus erythematosus (SLE) often self-manage ...
Glasgow, Scotland (ots/PRNewswire) - Poster Presentation PDB27 A new analysis of real-world data has shown that switching to Tresiba® (insulin degludec) is highly cost-effective and cost-saving for the treatment of type 1 and type 2 diabetes, respectively.[1] The analysis was presented today at the International Society for Pharmacoeconomics and Outcomes Research ...
Washington (ots/PRNewswire) - Despite increasing recognition of obesity as a disease, many barriers to effective care remain Few of the more than 90 million Americans with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment In Obesity Management ...
Teva Pharmaceutical Industries Ltd.
Amsterdam (ots/PRNewswire) - Advanced MS Care Programme will offer tailored support for MS patients People living with relapsing forms of Multiple Sclerosis (MS) can now access a new Patient Support Programme (PSP) that offers tailored help based on their individual beliefs and support needs. Officially announced ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for US/UK based media Merck to Present New Data on MS Portfolio: Rebif, Mavenclad, and Evobrutinib at ECTRIMS 2017 - Important safety and immune cell analyses further characterize the selective immune reconstitution approach of Mavenclad - Continued innovation with Rebif includes analysis of NEDA and use of MAGNIMS ...